TOP TEN perturbations for 39329_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39329_at
Selected probe(set): 208636_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39329_at (208636_at) across 6674 perturbations tested by GENEVESTIGATOR:

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):5.400674
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):-4.980772
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

B-CLL study 5 / normal bone marrow sample

Relative Expression (log2-ratio):-4.935584
Number of Samples:441 / 74
Experimental B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)

Relative Expression (log2-ratio):-4.2499247
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-8t28BBZ; post-infusion)
CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-4.2231073
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

CAR T cell study 4 (GFP; post-infusion) / CAR T cell study 4 (GFP; pre-infusion)

Relative Expression (log2-ratio):-4.205207
Number of Samples:3 / 3
Experimental CAR T cell study 4 (GFP; post-infusion)
CD8+ T cells transduced with GFP and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing GFP (control group). Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (GFP; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):4.131749
Number of Samples:3 / 4
Experimental expO kidney cancer study 1 (renal cell carcinoma, sarcomatoid; primary)
Primary tumor tissue samples obtained from the kidney of patients with renal cell carcinoma, sarcomatoid.
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic) / expO kidney cancer study 1 (granular cell carcinoma; primary)

Relative Expression (log2-ratio):4.0317135
Number of Samples:3 / 4
Experimental expO kidney cancer study 1 (clear cell adenocarcinoma, NOS; metastatic)
Metastatic tumor tissue obtained from a patient with primary clear cell adenocarcinoma (NOS) of the kidney.
Control expO kidney cancer study 1 (granular cell carcinoma; primary)
Primary tumor tissue samples obtained from the kidney of patients with granular cell carcinoma.

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):3.9017353
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

kidney transplantation study 14 (12 week) / normal B-cell (CD19+) sample

Relative Expression (log2-ratio):3.8781462
Number of Samples:3 / 5
Experimental kidney transplantation study 14 (12 week)
CD19+ B-cell samples derived from kidney transplant patients 12 weeks post-transplantation. Samples were collected 12 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal B-cell (CD19+) sample
CD19+ B-cell samples derived from healthy control subjects.